5 mL random urine

Test cannot be added to a urine sample previously utilized for urinalysis testing (LAB1160, LAB1164, LAB8379).

None

Drug of abuse screening tests are to be used for medical purposes only and not for non-medical purposes (e.g., employee, competitive athlete, or forensic testing).

Screen includes oxycodone and oxymorphone only.  For full drugs 

of abuse-urine panel, see "Drugs of Abuse Screen".



If quantitative confirmation is needed for oxycodone or oxymorphone, call the 

Laboratory at 356-3527. Allow up to seven days for confirmatory 

results. 

Quantitative confirmation is at an additional charge.



Approximate cut-off concentrations (ng/mL)*

-----------------------------------------

Oxycodone          300

Oxymorphone        291



*Assay does not cross-react with other opiates such as buprenorphine, 

codeine, heroin, hydrocodone, hydromorphone, and morphine, or with 

synthetic opioids such as fentanyl, meperidine, methadone, or 

propoxyphene.



References:

Belson MG, Simon HK, Sullivan K, Geller RJ.  The Utility of 

Toxicologic Analysis in Children with Suspected Ingestion.  Pediatr 

Emerg Care 1999;15:383-387.



Bast RP, Helmer SD, Henderson SR, Rogers MA, Shapiro WM, Smith RS.  

Limited Utility of Routine Drug Screening in Trauma Patients.  South 

Med J 2000;93:397-399.



Hammett-Stabler CA, Pesce AJ, Cannon DJ.  Urine Drug Screening in the 

Medical Setting.  Clinica Chimica Acta 2002;315:125-135.



Schiller MJ, Shumway M, Batki SL.  Utility of Routine Drug Screening 

in a Psychiatric Emergency Setting.  Psychiatric Services 2000;51:474-

478.



Sugarman JM, Rodgers GC, Paul RI.  Utility of Toxicology Screening in 

a Pediatric Emergency Department.  Pediatric Emergency Care.  

Pediatric Emergency Care 1997;13(3):194-197.

There is the possibility that other substances and/or factors may interfere with the test and cause erroneous results (e.g., technical or procedural errors). Call the lab at 319-356-3527 for additional information.

Enzyme Immunoassay (EIA)